Achieve Life Sciences, Inc. (ACHV)
ACHVNASDAQ-CMBiotechnology: In Vitro & In Vivo Diagnostic Substances
$6.71
-0.0800 (-1.18%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $697.68m
- P/E
- –
- EPS, last 4 quarters
- $-1.03
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.62 to $8.64
- Average volume
- 1.45m
- Previous close
- $6.79
Analysts
6 coveringStrong Buy6 buy, 0 hold, 0 sell
Targets a year out average $13.83, +106.1% from here
Earnings
next estimate $-0.2000Next report
Sep 2025
-16.7%
Dec 2025
-3.7%
Mar 2026
+36.7%
Jun 2026
-55.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$14.69m | -$14.73m | -$10.46m | -$18.39m |
| Net income | -$14.44m | -$14.66m | -$10.17m | -$74.77m |
News
8 latest- Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win RTTNews · Oct 23, 2026
- Achieve's Cytisinicline Shows 31% Smoking And Vaping Cessation Rate At One Year; Stock Up RTTNews · Oct 21, 2026
- Achieve Life Sciences Appoints Benjamin Halladay As CFO RTTNews · Oct 1, 2026
- Stifel Initiates Coverage of Achieve Life Sciences with BuyFintel · Sep 30, 2026
- Achieve Life Sciences Strengthens Cytisinicline Path To FDA Approval; Targets Decision In H1 FY27 RTTNews · Aug 11, 2026
- Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual MeetingMarketBeat · Jul 9, 2026
- Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired RTTNews · Jun 26, 2026
- FDA Issues CRL To Achieve Life Sciences For Cytisinicline NDA Over CGMP Manufacturing Concerns RTTNews · Jun 22, 2026
The company
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence. Achieve's New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- achievelifesciences.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.